Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
biphasic squamoid alveolar papillary renal cell carcinoma
genotype-phenotype correlation
germline mutation
mutation rate
papillary renal cell carcinoma
Journal
Human mutation
ISSN: 1098-1004
Titre abrégé: Hum Mutat
Pays: United States
ID NLM: 9215429
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
revised:
30
11
2021
received:
24
05
2021
accepted:
06
12
2021
pubmed:
10
12
2021
medline:
30
4
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
Hereditary papillary renal cell carcinoma (HPRC) is a rare inherited renal cancer syndrome characterized by bilateral and multifocal papillary type 1 renal tumors (PRCC1). Activating germline pathogenic variants of the MET gene were identified in HPRC families. We reviewed the medical and molecular records of a large French series of 158 patients screened for MET oncogenic variants. MET pathogenic and likely pathogenic variants rate was 12.4% with 40.6% among patients with familial PRCC1 and 5% among patients with sporadic PRCC1. The phenotype in cases with MET pathogenic and likely pathogenic variants was characteristic: PRCC1 tumors were mainly bilateral (84.3%) and multifocal (87.5%). Histologically, six out of seven patients with MET pathogenic variant harbored biphasic squamoid alveolar PRCC. Genetic screening identified one novel pathogenic variant MET c.3389T>C, p.(Leu1130Ser) and three novel likely pathogenic variants: MET c.3257A>T, p.(His1086Leu); MET c.3305T>C, p.(Ile1102Thr) and MET c.3373T>G, p.(Cys1125Gly). Functional assay confirmed their oncogenic effect as they induced an abnormal focus formation. The genotype-phenotype correlation between MET pathogenic variants and PRCC1 presentation should encourage to widen the screening, especially toward nonfamilial PRCC1. This precise phenotype also constitutes a strong argument for the classification of novel missense variants within the tyrosine kinase domain when functional assays are not accessible.
Substances chimiques
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-327Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Bossi, R. T., Saccardo, M. B., Ardini, E., Menichincheri, M., Rusconi, L., Magnaghi, P., Orsini, P., Avanzi, N., Borgia, A. L., Nesi, M., Bandiera, T., Fogliatto, G., & Bertrand, J. A. (2010). Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry, 49(32), 6813-6825. https://doi.org/10.1021/bi1005514
Cancer Genome Atlas Research Network, Linehan, W. M., Spellman, P. T., Ricketts, C. J., Creighton, C. J., Fei, S. S., Davis, C., Wheeler, D. A., Murray, B. A., Schmidt, L., Vocke, C. D., Peto, M., Al Mamun, A. A. M., Shinbrot, E., Sethi, A., Brooks, S., Rathmell, W. K., Brooks, A. N., Hoadley, K. A., & Zuna, R. (2016). Comprehensive molecular characterization of papillary renal-cell carcinoma. The New England Journal of Medicine, 374(2), 135-145. https://doi.org/10.1056/NEJMoa1505917
Chartier, S., Méjean, A., Richard, S., Thiounn, N., Vasiliu, V., & Verkarre, V. (2017). Biphasic squamoid alveolar renal cell carcinoma: 2 Cases in a family supporting a continuous spectrum with papillary type I renal cell carcinoma. The American Journal of Surgical Pathology, 41(7), 1011-1012. https://doi.org/10.1097/PAS.0000000000000870
Delahunt, B., & Eble, J. N. (1997). Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Modern Pathology, 10(6), 537-544.
Denize, T., Just, P. A., Sibony, M., Blons, H., Timsit, M. O., Drossart, T., Jakubowicz, D., Broudin, C., Morini, A., Molina, T., Vano, Y., Auvray-Kuentz, M., Richard, S., Mejean, A., Gimenez Roqueplo, A. P., Burnichon, N., & Verkarre, V. (2020). MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features. Modern Pathology, 34, 647-659. https://doi.org/10.1038/s41379-020-0645-6
Dharmawardana, P. G., Giubellino, A., & Bottaro, D. P. (2004). Hereditary papillary renal carcinoma type I. Current Molecular Medicine, 4(8), 855-868. http://doi.org/10.2174/1566524043359674
Fischer, J., Palmedo, G., von Knobloch, R., Bugert, P., Prayer-Galetti, T., Pagano, F., & Kovacs, G. (1998). Duplication and overexpression of the mutant allele of the MET proto oncogene in multiple hereditary papillary renal cell tumours. Oncogene, 17(6), 733-739. https://doi.org/10.1038/sj.onc.1201983
Holla, V. R., Elamin, Y. Y., Bailey, A. M., Johnson, A. M., Litzenburger, B. C., Khotskaya, Y. B., Sanchez, N. S., Zeng, J., Shufean, M. A., Shaw, K. R., Mendelsohn, J., Mills, G. B., Meric-Bernstam, F., & Simon, G. R. (2017). ALK: A tyrosine kinase target for cancer therapy. Molecular Case Studies, 3(1):a001115. https://doi.org/10.1101/mcs.a001115
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017). Renal cell carcinoma. Nature Reviews Disease Primers, 3, 17009. https://doi.org/10.1038/nrdp.2017.9
Inamura, K. (2017). Renal cell tumors: Understanding their molecular pathological epidemiology and the 2016 WHO classification. International Journal of Molecular Sciences, 18(10):2195. https://doi.org/10.3390/ijms18102195
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997). Activating mutations for the met tyrosine kinase receptor in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 94(21), 11445-11450. https://doi.org/10.1073/pnas.94.21.11445
Jiang, F., Richter, J., Schraml, P., Bubendorf, L., Gasser, T., Sauter, G., Mihatsch, M. J., & Moch, H. (1998). Chromosomal imbalances in papillary renal cell carcinoma: Genetic differences between histological subtypes. The American Journal of Pathology, 153(5), 1467-1473. https://doi.org/10.1016/S0002-9440(10)65734-3
Klatte, T., Pantuck, A. J., Said, J. W., Seligson, D. B., Rao, N. P., LaRochelle, J. C., Shuch, B., Zisman, A., Kabbinavar, F. F., & Belldegrun, A. S. (2009). Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clinical Cancer Research, 15(4), 1162-1169. https://doi.org/10.1158/1078-0432.CCR-08-1229
Lovly, C. M., & Pao, W. (2012). Escaping ALK inhibition: Mechanisms of and strategies to overcome resistance. Science Translational Medicine, 4(120), 120ps2. https://doi.org/10.1126/scitranslmed.3003728
Lubensky, I. A., Schmidt, L., Zhuang, Z., Weirich, G., Pack, S., Zambrano, N., Walther, M. M., Choyke, P., Linehan, W. M., & Zbar, B. (1999). Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. The American Journal of Pathology, 155(2), 517-526. https://doi.org/10.1016/S0002-9440(10)65147-4
Paumelle, R., Tulasne, D., Leroy, C., Coll, J., Vandenbunder, B., & Fafeur, V. (2000). Sequential activation of ERK and repression of JNK by scatter factor/hepatocyte growth factor in madin-darby canine kidney epithelial cells. Molecular Biology of the Cell, 11(11), 3751-3763. https://doi.org/10.1091/mbc.11.11.3751
Petrini, I. (2015). Biology of MET: A double life between normal tissue repair and tumor progression. Annals of Translational Medicine, 3(6), 82. https://doi.org/10.3978/j.issn.2305-5839.2015.03.58
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., Voelkerding, K., & Rehm, H. L. (2015). Standards and guidelines for he interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 17(5), 405-424. https://doi.org/10.1038/gim.2015.30
Salvi, A., Marchina, E., Benetti, A., Grigolato, P., De Petro, G., & Barlati, S. (2008). Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients. International Journal of Oncology, 33(2), 271-276.
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., Capelletti, M., Shimamura, T., Ercan, D., Stumpfova, M., Xiao, Y., Weremowicz, S., Butaney, M., Heon, S., Wilner, K., … Jänne, P. A. (2011). A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Research, 71(18), 6051-6060. https://doi.org/10.1158/0008-5472.CAN-11-1340
Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., … Zbar, B. (1997). Germline and somatic mutations in the tyrosine kinase domain of the MET proto oncogene in papillary renal carcinomas. Nature Genetics, 16(1), 68-73. https://doi.org/10.1038/ng0597-68
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., Vocke, C., Brown, J. A., Jenkins, R., Richard, S., Bergerheim, U., Gerrard, B., Dean, M., Linehan, W. M., & Zbar, B. (1999). Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 18(14), 2343-2350. https://doi.org/10.1038/sj.onc.1202547
Schmidt, L., Junker, K., Weirich, G., Glenn, G., Choyke, P., Lubensky, I., Zhuang, Z., Jeffers, M., Vande Woude, G., Neumann, H., Walther, M., Linehan, W. M., & Zbar, B. (1998). Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Research, 58(8), 1719-1722.
Schmidt, L., & Linehan, W. M. (2016). Genetic predisposition to kidney cancer. Seminars in Oncology, 43(5), 566-574. https://doi.org/10.1053/j.seminoncol.2016.09.001
Schmidt, L., Nickerson, M. L., Angeloni, D., Glenn, G. M., Walther, M. M., Albert, P. S., Warren, M. B., Choyke, P. L., Torres-Cabala, C. A., Merino, M. J., Brunet, J., Bérez, V., Borràs, J., Sesia, G., Middelton, L., Phillips, J. L., Stolle, C., Zbar, B., Pautler, S. E., & Linehan, W. M. (2004). Early onset hereditary papillary renal carcinoma: Germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. The Journal of Urology, 172(4 Pt 1), 1256-1261. https://doi.org/10.1097/01.ju.0000139583.63354.e0
Tovar, E. A., & Graveel, C. R. (2017). MET in human cancer: Germline and somatic mutations. Annals of Translational Medicine, 5(10), 205. https://doi.org/10.21037/atm.2017.03.64
Zbar, B., Glenn, G., Lubensky, I., Choyke, P., Walther, M. M., Magnusson, G., Bergerheim, U. S., Pettersson, S., Amin, M., & Hurley, K. (1995). Hereditary papillary renal cell carcinoma: Clinical studies in 10 families. The Journal of Urology, 153(3 Pt 2), 907-912.
Zbar, B., Tory, K., Merino, M., Schmidt, L., Glenn, G., Choyke, P., Walther, M. M., Lerman, M., & Linehan, W. M. (1994). Hereditary papillary renal cell carcinoma. The Journal of Urology, 151(3), 561-566. https://doi.org/10.1016/s0022-5347(17)35015-2
Zhang, Y., Xia, M., Jin, K., Wang, S., Wei, H., Fan, C., Wu, Y., Li, X., Li, X., Li, G., Zeng, Z., & Xiong, W. (2018). Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Molecular Cancer, 17(1), 45. https://doi.org/10.1186/s12943-018-0796-y
Zhuang, Z., Park, W. S., Pack, S., Schmidt, L., Vortmeyer, A. O., Pak, E., Pham, T., Weil, R. J., Candidus, S., Lubensky, I. A., Linehan, W. M., Zbar, B., & Weirich, G. (1998). Trisomy 7 harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 20(1), 66-69. http://doi.org/10.1038/1727